High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort

• Published in: The American journal of gastroenterology Vol. 119; no. 8; pp. 1624 - 1627
• Main Authors: Barritt, 4th, A Sidney, Yu, Feng, Mospan, Andrea R, Newsome, Phillip N, Roden, Michael, Morris, Heather L, Loomba, Rohit, Neuschwander-Tetri, Brent A
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.08.2024
• Subjects: Alcohol use; Enrollments; Liver cirrhosis; Liver diseases; Metabolism; Patients; Pharmaceuticals; Stigma; United States > US
• ISSN: 0002-9270; 1572-0241; 1572-0241
• DOI: 10.14309/ajg.0000000000002796

This study investigates the applicability of the new metabolic dysfunction-associated steatotic liver disease (MASLD) nomenclature to the real-world TARGET-NASH US adult cohort. The new MASLD/metabolic steatohepatitis nomenclature was applied to patients enrolled with pragmatic diagnoses of nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH), and NASH cirrhosis and concordance were determined between the definitions. Approximately 99% of TARGET-NASH participants met the new MASLD diagnostic criteria. Approximately 1,484/1,541 (96.3%, kappa 0.974) nonalcoholic fatty liver patients (metabolic dysfunction-associated steatotic liver), 2,195/2,201 (99.7%, kappa 0.998) NASH patients (metabolic steatohepatitis), and 1,999/2,003 (99.8%, kappa 0.999) NASH cirrhosis patients met the new criteria. The new MASLD nomenclature is highly concordant with the previous TARGET-NASH pragmatic definitions.